TY - JOUR T1 - Combined oral contraceptives and risk of venous thromboembolism: there is higher risk in new generations compared to second generations, but paradoxically not in norgestimate-containing-pills JF - Evidence Based Medicine JO - Evid Based Med SP - 189 LP - 189 DO - 10.1136/ebmed-2015-110249 VL - 20 IS - 5 AU - Geneviève Plu-Bureau Y1 - 2015/10/01 UR - http://ebm.bmj.com/content/20/5/189.abstract N2 - Commentary on: Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case–control studies using the QResearch and CPRD databases. BMJ 2015;350:h2135.OpenUrlAbstract/FREE Full TextFor many years, it has been well documented that combined oral contraceptives (COCs) increase the risk of venous thromboembolism events (VTEs). The VTE risk may vary according to different characteristics of COCs, such as oestrogen dose and type of progestins. COCs are some of the most commonly proposed birth control methods, used by several million women worldwide. Formulations of COCs have dramatically changed over the past 50 years. The new combinations containing cyproterone, drospirenone or norgestimate, associated with low doses of ethinyl-oestradiol, have been recently investigated, but some studies have insufficient power to estimate the risks for these recent … ER -